ArticleMacromolecular bioscience2026
Dual-Functional Antibiotic Adjuvants Based on Antibacterial Polyesters With Guanidinium and Boronic Acid Motifs.
Article in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study addresses the challenge of antimicrobial resistance in Gram-negative bacteria by developing a novel class of biodegradable polymeric antibiotic adjuvants. We have engineered cationic polyesters functionalized with guanidinium and phenylboronic acid (PBA) groups through the one-pot thiol-Michael addition post-modification to create a dual-targeting mechanism against the bacterial outer membrane (OM). This design combines the membrane-disruptive action of guanidinium with the specific binding capability of PBA to lipopolysaccharides. The relationships between structure of the polymers and their antibacterial ability or cytocompatibility were explored. The optimized polymer, G95-BA5, exhibited potent intrinsic bactericidal activity and good biocompatibility. It also demonstrated remarkable in vitro synergy with rifampicin against multidrug-resistant pathogens, achieving fractional inhibitory concentration indices as low as 0.06 by significantly enhancing the outer membrane permeability. In a lethal murine peritonitis model, the combination of G95-BA5 and rifampicin provided 100% survival, drastically reduced bacterial burden in vital organs, and controlled systemic inflammation. This work establishes an effective polymer platform for overcoming the OM permeability-based resistance and revitalizing existing antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.